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ABSTRACT 
Objective: To develop and validate a simple and rapid reversed phase high performance liquid chromatographic (RP-HPLC) method for the 
determination of Gemifloxacin (GFX) in human urine. 
Methods: GFX was isolated from urine samples after acidification using methylene chloride. Good chromatographic separation was achieved using C18
Results: GFX has been eluted at 7.5 min. Linearity was obtained over a concentration range of 20-200 ng/ml (r2>0.999). The extraction recovery of 
GFX from urine samples was 60%. The proposed method demonstrated excellent intra-and inter-day precision and accuracy within 1.19% and 
100.65 %, respectively. The limit of detection (LOD) was found to be 6.3 ng/ml. 
 
Ultrasphere (250 mm × 4.6 mm, 5 µm.) analytical column maintained at 25 °C. The mobile phase consisted of methanol and 0.1 M phosphate buffer pH 3 
in the ratio of (48: 52, v/v), respectively. The analysis time was 10 min at a 1.0 ml/min flow rate. The UV detection was carried out at 272 nm.  
Conclusion: Simple and accurate RP-HPLC method for determination of GFX in human urine was developed and validated. The method was 
successfully applied for determination of GFX in human urine samples from healthy volunteers up to 24 hours after oral administration of 320 mg 
gemi floxacin tablets.  
Keywords: Gemifloxacin, RP-HPLC, Human urine. 
 
INTRODUCTION 
Since the introduction of nalidixic acid as the first quinolone; various 
structural modifications have been introduced, that resulted in 
production of second-, third-, and fourth-generation fluoroquinolones 
with improved antibacterial activity and pharmacological properties 
[1]. The US Food and Drug Administration (FDA) has been approved 
Gemifloxacin as a fourth generation fluoroquinolone [2]. Gemifloxacin 
[(R,S)-7-[(4Z)-3-(aminomethyl)-4-(methoxyimino)-1-pyrrolidinyl]-1-
cyclopropyl-6-fluoro-1,4-dihydro-4-oxo1,8-naphthyridine-3-carboxylic 
acid] (fig. 1), is a fluoroquinolone antibacterial agent, it is active 
against both gram-positive and gram-negative bacteria [2-4]. 
Gemifloxacin used for the treatment of urinary tract and respiratory 
tract infections [5, 6]. It has been found that Gemifloxacin was four 
times more potent than moxifloxacin against S. pneumonia (including 
multi-drug resistant strains [MDRSP]) [7, 8]. Gemifloxacin has two 
mechanisms of action. Firstly; depends on blocking of bacterial DNA 
replication by binding to an enzyme called DNA gyrase (topoisomerase 
II), which allows the untwisting required to replicate one DNA double 
helix into two. Notably the drug has 100 times higher affinity for 
bacterial DNA gyrase than for mammalian ones. Secondly, The 
bactericidal action of Gemifloxacin results from inhibition of the 
enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which 
are required for bacterial DNA replication, transcription, repair, and 
recombination [9]. The important aspect of the routine use of any drug 
is to understand the correlations of drug levels with drug action. The 
accurately quantifying of the drugs in biological matrices such as 
blood, serum, urine, and tissue samples is important for therapeutic 
drug monitoring. Validated results are essential for accurate drug 
monitoring, clinical decisions and further treatment options. Accurate, 
reproducible, and specific method for the quantification of 
Gemifloxacin is compulsory. Therefore several methods have been 
developed for the analysis of Gemifloxacin in pharmaceutical 
preparations or human plasma such as spectrophotometric techniques  
[10–19], capillary electrophoresis [20], high performance liquid 
chromatography [21–29], LC-mass spectrometry [30–33], microchip 
electrophoresis [34], chemiluminescence [35] and potentiometry [36]. 
In view of the fact that more than 20% of Gemifloxacin is excreted 
unchanged in urine, so determination of Gemifloxcin in urine 
samples may be a useful analytical tool. However, as much as we 
know; there is no published method for determination of 
Gemifloxacin in human urine using reversed phase high 
performance liquid chromatographic method with UV-detector. 
Urine is a more readily available biological medium compared to 
plasma. It is easier to be obtained and less invasive. The aim of this 
work is to develop and validate a simple and rapid method for 
determination of Gemifloxacin in human urine. 
 
 
Fig. 1: Chemical structure of Gemifloxacin 
 
MATERIALS AND METHODS 
Reagents and chemicals 
All the chemicals were of Analytical grade, and the solvents were of 
HPLC grade. High purity water was obtained by filtration of distilled 
water through 0.45 μm membrane filter (Millipore, Ireland) and it 
was used throughout the study. Gemifloxacin mesylate 
(Purity,>98%) was purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Factive® tablet equivalent to 320 mg Gemifloxacin was 
obtained from local market. Blank human urine was collected from 
healthy volunteer’s stored at-20 °C. Methanol was obtained from 
Tedia Company (1000 Tedia Way, Fairfield, OH 45014, USA). 
Phosphate buffer 0.1M was prepared from sodium dihydrogen 
phosphate and pH was adjusted by orthophosphoric acid. 
Anhydrous sodium di hydrogen phosphate monohydrate and 
orthophosphoric acid were purchased from El-Nasr Pharmaceutical 
Chemicals Company (ADWIC) (Cairo, Egypt). 
Instrumentation  
The HPLC system consisted of a Shimadzu LC-20AD Prominence 
liquid chromatogram equipped with a Rheodyne injector valve with 
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a 20 µl loop and a SPD-20A UV detector operated at 272 nm. C18 
(Thermo, Beckman coulter™
Standards and quality control samples preparation  
, USA) ultra sphere column (250 mm × 
4.6 mm, 5 µm.),  
A 1.0 μg/ml stock solution was prepared in distilled water. Working 
solutions were prepared by serial dilutions of the stock solution. 
Calibration standards were prepared in human urine at 20, 30, 50, 
90, 100, 110, 170 and 200ng/ml. Low, med and high quality control 
(QC) samples were prepared in human urine at concentration levels 
of 30, 100 and 170 ng/ml, respectively. All solutions were filtered 
through a 0.45 µm filters to eliminate any solid impurity. All samples 
were protected from light using aluminum foil and stored at-20 ºC 
until being used for analysis. 
Liquid-liquid extraction (LLE) procedures  
The urine standards/quality control samples were filtered using 0.45 
µm filter to eliminate any solid impurities. Extraction of Gemifloxacin 
from human urine was achieved using one ml aliquot of each sample 
and five ml methylene chloride; then acidified with one ml (1N) 
hydrochloride. The samples were vortex mixed for 10 min, and 
centrifuged at 3500 rpm for 5 min at room temperature (RT). Four ml 
of methylene chloride from each sample was quantitavely transferred 
into a clean glass tube. Samples were then evaporated to dryness 
under a stream of nitrogen for about 5 min. The dried extracts were 
reconstituted in 0.2 ml (methanol: 0.1 M sodium dihydrogen 
phosphate (48:52 v/v), pH 3 prior to injection and a 20 µl was injected. 
Chromatographic conditions 
Isocratic elution using mobile phase consisted of a mixture of methanol 
and 0.1 M sodium dihydrogen phosphate (48:52 v/v), adjusted at pH 3 
with orthophosphoric acid. The mobile phase was filtered through 0.45 
µm Millipore membrane filter and degassed by sonication for 30 min 
before use. Detection was achieved at 272 nm. The column was operated 
at 25 °C. Run time was 10 min at a flow rate of 1.0 ml/min.  
Validation 
The resulting HPLC-UV method for determination of Gemifloxacin in 
human urine was validated according to the FDA guidelines [37]. 
Selectivity, linearity, accuracy, precision, recovery, stability and 
sensitivity experiments were performed. The  calibration curves 
were evaluated based on back-calculated standard results. 
Selectivity is the ability of a method to determine accurately the 
analyte of interest in the presence of other components in a sample 
matrix under the stated conditions of the test. To demonstrate the 
specificity of the analytical procedure, six different blank urine 
samples obtained from different healthy volunteers were analyzed 
for peaks interfering with the detection of the analytes. 
The linearity of the method was determined at seven different 
concentrations that ranged from 20 to 200 ng/ml. Each 
concentration was injected three times. 
The accuracy of an analytical procedure measures the closeness of 
measured values to the true values. It was evaluated as the 
percentage relative error between the measured mean 
concentrations and taken concentrations. Low, med and high  QC 
samples at concentration levels of 30, 100 and 170 ng/ml, 
respectively, were analyzed through three validations. 
The precision of the method was investigated with respect to 
repeatability. For intra-day and inter-day precision and acceptable 
repeatability of the results within one day and day-to-day was 
observed. The precision of the method was analyzed as % RSD 
throughout the linear range of concentrations. 
Extraction recovery from human urine was determined by 
comparing the analyte responses of pre-extraction spiked samples at 
three sets of low, mid, and high quality control concentrations to 
those of post-extraction spiked samples. Each concentration 
repeated three times. 
The stability of Gemifloxacin in urine samples was investigated by 
preparing spiked samples at two different concentrations (30 
and170 ng/ml) three times. Freeze/thaw stability was calculated by 
analyzing low quality control samples (30 ng/ml) and high quality 
control samples (170 ng/ml) over three freeze/thaw cycles (n = 3). 
Samples were frozen at − 20 ºC for at least 24 hours for the first 
cycle; thawed at room temperature and then frozen at −20 PºPC for at 
least 12 hours for each freeze/thaw cycle. Stability in thawed matrix 
was evaluated by analyzing low quality control (30 ng/ml) and high 
quality control (170 ng/ml) samples (n =3) from −20  °C storage. 
Thawed matrix was allowed to sit at room temperature for 4 hours 
and 24 hours before extraction. Long term stability was investigated 
at low and high quality control sample levels after storing for 30 
days at-20 °C.  
To investigate the effect of variable endogenous matrix components 
from multiple individuals, quality control samples (n = 3) at a 
concentration of 30 ng/ml of Gemifloxacin were spiked into six 
different human blank urine samples from six different individuals, 
extracted and analyzed as described above. 
The sensitivity of the analytical technique was expressed as the limit 
of detection (LOD) which was determined as the lowest 
concentration of analyte that produce peak height at 3: 1 the noise 
level and the limit of quantitation (LOQ) which was determined as 
the lowest concentration of analyte that produce peak height at least 
at 10: 1 the noise level and could be determined with adequate 
precision of 20% and accuracy of 80–120%. 
Robustness of the method was accomplished by designed 
modifications made to the method parameters such as composition, 
flow rate and pH of the mobile phase. 
The unchanged portion of GFX that excreted in urine will be 
tremendously higher than the validated calibration curve. The ability 
to analyze urine samples originally above the upper limit of the 
calibration range was validated by analyzing three replicates of a 
100 ng/ml QC sample as 10000-fold dilutions with blank urine. 
 
Fig. 2: HPLC-UV chromatogram of (200 ng/ml) of Gemifloxacin 
spiked urine sample 
 
RESULTS AND DISCUSSION 
Method development 
HPLC method coupled to UV detection was developed and fully 
validated for the determination of Gemifloxacin with satisfactory 
accuracy and precision. This method was applied for the analysis 
of the studied drug in spiked human urine using the rapid and 
simple procedure. The method was optimized to obtain acceptable 
theoretical plates and a good separation with sufficient sensitivity 
and suitable peak symmetry. RP-CR18Rcolumn was suitable for 
separation of GFX from other endogenous components in human 
urine with adequate resolution. The chromatographic conditions 
were optimized through several trials to achieve optimum 
resolution, high sensitivity, and symmetrical peak shape for 
Gemifloxacin. Different organic modified such as methanol and 
acetonitrile with different percentages of phosphate buffer were 
tested. An isocratic mobile phase with a mobile phase consists of 
methanol and phosphate buffer pH 3 (48:52, v/v) showed 
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excellent peak shape and chromatographic resolutions from 
endogenous matrix component peaks (fig. 2); repeated injections 
showed no co-elution of any interfering peak with target analyte 
peak. The elution of the GFX was achieved at 7.5 min and a run 
time of 10 min. Precision of retention time was examined to 
evaluate the system suitability. Intra-day repeatability (n=5) and 
inter-day precision (n=11) were evaluated. The optimized 
chromatographic conditions showed excellent peak shape and 
repeatability in addition to rapid determination within 10 min. 
Method validation 
A reversed phase liquid chromatographic method coupled with UV 
detector was developed to provide a rapid analysis of GFX. The most 
important advantage of LC method is the achievement of good 
resolution with acceptable peak symmetry in a reasonable analysis 
time. However, fully validated method is also mandatory to ensure 
the validity of the method for accurate and precise determination 
and monitoring GFX in human urine samples. 
Specificity  
The proposed method showed good specificity in blank urine samples 
from six different individuals. There was no significant chromatographic 
peak (greater than 20% of the mean response at the lower limit of 
quantification) detected at the expected retention times of the target 
analyte. No co-elution with endogenous matrix component peaks was 
observed after several injections (more than 50 injections)  
Linearity and correlation coefficient  
The average correlation coefficient from three validation runs 
was>0.999 which was evaluated by the least-squares regression 
method. Precision of the calibrators (measured as the percent 
relative standard deviation %RSD) of back calculated standards was 
within 3.3%. Accuracy of the residuals (measured as the percent 
difference from the nominal concentration %DFN) was within 
±5.0%. LLOQ was established as the lowest concentration on the 
calibration curve with accuracy and precision within±20% (20 
ng/ml), LOD was found to be 6.3 ng/ml and linearity was obtained 
over the concentration range of (20 ng/ml to 200 ng/ml). Sensitivity 
of the proposed method makes the method comparable to other 
more advanced hyphenated techniques such as LC-MS which may be 
not available in all research laboratories. 
The high rP2Pvalue gave an indication of the good linearity, and the low 
values of standard deviations of the intercept and the slope gave an 
indication of the significant validity of the calibration points used for 
constructing the calibration curve. 
Precision and accuracy 
The precision and accuracy at the low, medium and high 
concentration of GFX in urine were evaluated as shown in table 1. 
Intra-and inter-day precision (relative standard deviations % RSD) 
was within 1.42 and 1.19%, respectively. Intra-and inter-day 
accuracy was less than±3%. 
  
Table 1: Intra-and inter-day precision and accuracy calculated from quality control samples for GFX 
QC level Conc. ng/ml Inter-day (n=11) Intra-day (n=5) 



























LLE is known to provide clean extracts in addition to simplicity and 
low cost in comparison to solid phase extraction (SPE). Optimization 
of the transfer of analytes from urine matrix to the organic layer is 
essential to obtain the highest possible extraction recovery; different 
extracting solvents and pHs were investigated. The aim of sample 
clean-up procedures, not only high extraction recovery, but also 
cleanliness of the extracts which can be confirmed by the elution 
profiles of unknown endogenous component peaks in blank samples. 
On the other hand, absence of co-elution and interferences are 
another advantages of the proposed method. The extraction 
recovery of the analyte from urine matrix using the optimized liquid-
liquid extraction method was 58, 56 and 60%, for 30, 100 and 170 
ng/ml, respectively. 
Stability studies 
All stability experiments showed precision within 2.0% and 
accuracy within±0.5 % (table 2) 
Dilution integrity 
The intra-assay precision and accuracy for the diluted QC pools and 
over the curve diluted samples showed was within the acceptable 
ranges. 
Inter-subject variability 
Variable endogenous matrix components from different donors may 
significantly affect precision and accuracy of the results. Validity of 
the method in different matrix sources should be investigated during 
method development and validation. Inter-subject variability 
experiments showed acceptable accuracy and precision within±4.6 
% (table 3). The proposed chromatographic conditions showed 
excellent resolution in different urine sources. 
Monitoring Gemifloxacin in human urine after oral 
administration  
Blank urine was collected from three healthy volunteers free from 
Gemifloxacin and stored at −20 ° C. Non-smokers and healthy 
volunteers participated in the study after giving informed written 
consent. After an overnight fast, the volunteers reported to the study 
centre received a single dose of FactiveP®P tablet (labelled to contain 
Gemifloxacin mesylate equivalent to 320 mg Gemifloxacin per 
tablet) in 150 ml water. Urine samples were collected from each 
volunteer after: 0 (pre-dose), 2, 4, 6, 8, 12 and 24 h. For each 
collection period, 10 ml aliquot was retained and stored at −20 °C. 
0.1 ml of each sample was diluted to 1000 ml with blank urine. 0.1 
ml of each sample was analyzed as in section 2, 3, 2; endogenous 
matrix component peaks were chromatographically resolved from 
target peak (fig. 3). As shown in fig. 4; the proposed method was 
found to be useful for accurate determination and monitoring of the 
unchanged GFX in urine samples after oral administration as well as 
any further pharmacokinetics and toxicity studies. 
 
 
Fig. 3: HPLC-UV chromatogram of Gemifloxacin in human urine 
sample collected after 24 hours of oral administration 
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Table 2: Precision and accuracy calculated from stability experiments for GFX 
Experiment (n=3)  Concentration (ng/ml) Mean±SD (ng/ml) Precision (%RSD) Accuracy (%DFN)  










Thawed matrix stability 









Thawed matrix stability 









Long term stability 









Table 3: Inter-subject variability experiment results of six different urine samples fortified with Gemifloxacin 
Individual source Concentration (ng/ml) Mean (±SD) (ng/ml) Precision (%RSD) Accuracy (%DFN)  
1 30.00 28.71±0.64 2.24 -0.040 
2 30.00 29.69±1.18 3.98 -0.010 
3 30.00 31.28±1.42 4.56  0.040 
4 30.00 28.87±0.93 3.23 -0.040 
5 30.00 28.89±0.56 1.93 -0.040 
6 30.00 29.09±1.03 3.53 -0.030 
 
 
Fig. 4: The concentration-time curve of Gemifloxacin in urine 




A simple, precise and reproducible HPLC-UV method for 
determination of Gemifloxacin in human urine has been developed. 
This study provided a simple and low cost liquid–liquid extraction 
method compared with other methods such as solid-phase 
extraction. The sensitivity of the assay was satisfied and the method 
was successfully applied to the analysis of Gemifloxacin in human 
urine samples after oral administration of Gemifloxacin capsules. 
The method was fully validated with sufficiently precise, accurate 
results.  
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